Liqin Xu
-
- Peptidase Inhibition and Analysis 4
- Lung Cancer Research Studies 2
- Cancer survivorship and care 2
-
- Immunotherapy and Immune Responses 2
-
- Glycosylation and Glycoproteins Research 3
- Receptor Mechanisms and Signaling 2
-
- Childhood Cancer Survivors' Quality of Life 2
-
- Neonatal Respiratory Health Research 2
- Co-authors
- Jian FengHassan ElHawaryJohnny Ionut EfanovJoshua VorstenboschJad Abi‐RafehAslan BaradaranJianfei HuangHuijun Zhu
- Cited by
- Cancer ResearchOncologyRheumatology
In The Last Decade
Liqin Xu
19 papers receiving 370 citations
Peers
Comparison fields: 5 of 88
- Cancer Research 61
- Oncology 91
- Rheumatology 48
- Complementary and Manual Therapy 7
- Immunology 58
Countries citing papers authored by Liqin Xu
This map shows the geographic impact of Liqin Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liqin Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liqin Xu more than expected).
Fields of papers citing papers by Liqin Xu
This network shows the impact of papers produced by Liqin Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liqin Xu. The network helps show where Liqin Xu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Liqin Xu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 6 | |
| 3 | 2023 | 2 | |
| 4 | 2022 | 2 | |
| 5 | 2021 | 84 | |
| 6 | 2021 | 4 | |
| 7 | 2020 | 14 | |
| 8 | 2019 | 8 | |
| 9 | 2019 | 72 | |
| 10 | 2019 | 0 | |
| 11 | 2019 | 1 | |
| 12 | 2019 | 7 | |
| 13 | 2018 | 11 | |
| 14 | 2017 | 1 | |
| 15 | 2017 | 12 | |
| 16 | 2016 | 41 | |
| 17 | 2015 | 17 | |
| 18 | 2015 | 17 | |
| 19 | High expression of MAGE-A9 in tumor and stromal cells of non-small cell lung cancer was correlated with patient poor survival. | 2015 | 30 |
| 20 | 2014 | 44 |
About Liqin Xu
Liqin Xu is a scholar working on Oncology, Orthopedics and Sports Medicine and Immunology, having authored 20 papers that have together received 374 indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (4 papers), Glycosylation and Glycoproteins Research (3 papers), Childhood Cancer Survivors' Quality of Life (2 papers), Neonatal Respiratory Health Research (2 papers), Lung Cancer Research Studies (2 papers), Cancer survivorship and care (2 papers), Immunotherapy and Immune Responses (2 papers) and Receptor Mechanisms and Signaling (2 papers). The work is most often cited by research in Cancer Research (61 citations), Oncology (91 citations) and Rheumatology (48 citations). Liqin Xu has collaborated with scholars based in China, Australia and Canada. Frequent co-authors include Jian Feng, Hassan ElHawary, Johnny Ionut Efanov, Joshua Vorstenbosch, Jad Abi‐Rafeh, Aslan Baradaran, Jianfei Huang, Huijun Zhu, Songshi Ni and Guoxin Mao. Their work appears in journals such as Oncotarget, Integrative Cancer Therapies, Lung, Oncology Reports and Seminars in Plastic Surgery.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.